治疗所致淋巴细胞减少对胶质母细胞瘤患者生存影响的系统综述与汇总分析
该系统综述与汇总分析纳入10项研究共1718例接受化疗和放疗的胶质母细胞瘤患者,评估淋巴细胞减少与总生存的关联。汇总分析显示淋巴细胞减少与死亡风险增加相关,时间点研究汇总HR为1.78(95%CI 1.46-2.17,P<0.00001),时间范围研究汇总HR为1.38(95%CI 1.24-1.55,P<0.00001),研究间无显著异质性。作者认为淋巴细胞减少是胶质母细胞瘤的不良预后因素。
要点
- 淋巴细胞减少与胶质母细胞瘤患者死亡风险增加相关,时间点研究汇总HR为1.78(95%CI 1.46-2.17,P<0.00001)。
- 时间范围研究汇总HR为1.38(95%CI 1.24-1.55,P<0.00001),研究间无显著异质性。
- 全部研究淋巴细胞减少平均汇总发生率为31.8%,时间点研究为11.8%,时间范围研究为39.9%。
核心结论
- 淋巴细胞减少与胶质母细胞瘤患者总生存期缩短相关,汇总HR为1.78(95%CI 1.46-2.17,P<0.00001)和1.38(95%CI 1.24-1.55,P<0.00001),提示淋巴细胞减少是不良预后因素。
研究设计与样本
- 遵循PRISMA指南,系统检索MEDLINE数据库及ASTRO、ASCO、SNO年会摘要,最终纳入10项研究共1718例接受化疗和放疗的胶质母细胞瘤患者。
- 采用逆方差加权随机效应模型进行汇总分析,生成淋巴细胞减少与总生存关联的风险比汇总估计值。
主要发现
- 104项初筛研究中10项符合纳入标准,共代表1718例患者。
- 淋巴细胞减少的截断值范围为400-1100 cells/uL,且发生时间点各异。
- 全部研究淋巴细胞减少平均汇总发生率为31.8%,时间点研究为11.8%,时间范围研究为39.9%。
- 时间点研究中淋巴细胞减少与死亡风险增加相关,汇总HR为1.78(95%CI 1.46-2.17,P<0.00001)。
- 研究间无显著异质性。
关键数值与推荐
- 淋巴细胞减少截断值范围为400-1100 cells/uL,发生时间点各异。
- 时间点研究定义为放疗后约2个月时存在淋巴细胞减少,时间范围研究定义为治疗开始至放疗后约2个月内任何时间发生淋巴细胞减少。
- 时间点研究汇总HR为1.78(95%CI 1.46-2.17,P<0.00001);时间范围研究汇总HR为1.38(95%CI 1.24-1.55,P<0.00001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 淋巴细胞减少的截断值范围宽(400-1100 cells/uL),且发生时间点各异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE(S): Treatment related lymphopenia is a known toxicity for glioblastoma (GBM) patients and several single-institution studies have linked lymphopenia with poor survival outcomes. We performed a systematic review and pooled analysis to evaluate the association between lymphopenia and overall survival (OS) for GBM patients undergoing chemotherapy and radiation therapy (RT). MATERIALS/METHODS: Following PRISMA guidelines, a systematic literature review of the MEDLINE database and abstracts from ASTRO, ASCO, and SNO annual meetings was conducted. A pooled analysis was performed using inverse variance-weighted random effects to generate a pooled estimate of the hazard ratio of association between lymphopenia and OS. RESULTS: Ten of 104 identified studies met inclusion criteria, representing 1,718 patients. The lymphopenia cutoff value varied (400-1100 cells/uL) and as well as the timing of its onset. Studies were grouped as time-point (i.e., lymphopenia at approximately 2-months post-RT) or time-range (any lymphopenia occurrence from treatment-start to approximately 2-months post-RT. The mean overall pooled incidence of lymphopenia for all studies was 31.8%, and 11.8% vs. 39.9% for time-point vs. time-range studies, respectively. Lymphopenia was associated with increased risk of death, with a pooled HR of 1.78 (95% CI 1.46-2.17, P < 0.00001) for the time-point studies, and a pooled HR of 1.38 (95% CI 1.24-1.55, P < 0.00001) for the time-point studies. There was no significant heterogeneity between studies. CONCLUSION: These results strengthen observations from previous individual single-institution studies and better defines the magnitude of the association between lymphopenia with OS in GBM patients, highlighting lymphopenia as a poor prognostic factor.
引用
- Saeed AM, Bentzen SM, Ahmad H, et al. Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. Radiat Oncol. 2024. PMID: 38481255. doi:10.1186/s13014-023-02393-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。